ABSTRACT
Objective To investigate the expression of multidrug resistance protein 1 (MDR1) and brain and acute leukemia cytoplasm (BAALC) genes and its relationship with prognosis in patients with newly diagnosed acute myeloid leukemia (AML).Methods A total of 100 adults with newly diagnosed AML were enrolled in the study.All patients were treated with anthracyclines induced chemotherapy combined with cytarabine.The expression levels of MDR1 and BAALC genes were detected,and the relationships with the clinical characteristics of patients with AML,genetic type,therapeutic effect and prognosis were analyzed.Results There was no significant differences in white blood cells,hemoglobin and platelet between patients with high and low expression of MDR1 gene and BAALC gene (P>0.05).There were significant differences in the expression level of MDR1 gene between patients with different chromosome risk stratification (P0.05).After chemotherapy intervention,CR of patients with high expression of MDR1 gene was significantly lower than patients with low expression of MDR1 gene (60.78% vs.87.76%)(P0.05).Comparison of median overall survival (OS) and overall survival (OS) in patients with high and low expression of MDR1 gene.The difference was statistically significant (P0.05).Conclusion Compared with the expression of BAALC gene,the value of expression of MDR1 gene is higher in evaluating the curative effect in patients with newly diagnosed AML.Combined detection of MDR1 and BAALC genes can improve the accuracy in predicting the prognosis of patients.